Literature DB >> 11259991

Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.

D W Kaufman1, J P Kelly.   

Abstract

AIMS: Various nonsteroidal anti-inflammatory drugs are known to increase the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. The relationship between salicylate treatment and these conditions is not known.
METHODS: A case-control study was conducted in four countries in Europe from 1989 to 1995.
RESULTS: Among 373 cases and 1720 controls, the multivariate relative risk estimate for any salicylate use in the previous week was 1.3 (95% confidence interval, 0.8-2.2); no statistically significant elevations were observed for single ingredient preparations or for salicylate-containing combination products.
CONCLUSIONS: Acetylsalicylic acid and other salicylates are not associated with a measurable increase in the risk of these rare but severe reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259991      PMCID: PMC2014441          DOI: 10.1111/j.1365-2125.2001.01323.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

Review 1.  Severe adverse cutaneous reactions to drugs.

Authors:  J C Roujeau; R S Stern
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

2.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

3.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

Review 4.  An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.

Authors:  J P Kelly; A Auquier; B Rzany; L Naldi; S Bastuji-Garin; O Correia; S Shapiro; D W Kaufman
Journal:  J Clin Epidemiol       Date:  1995-09       Impact factor: 6.437

  4 in total
  1 in total

1.  Aggrenox (Asasantin retard)-induced Stevens-Johnson syndrome.

Authors:  Tun Jao; Tsung-Hua Tsai; Jiann-Shing Jeng
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.